Navigation Links
Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Date:11/19/2007

or about 90 percent of the primary malignant liver tumors in adults.(1,2) Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally.(3) More than 600,000 cases of liver cancer are diagnosed worldwide each year(3) (about 19,000 in the United States,(4) 54,000(5) in Europe,(6) and 390,000 in China, Korea and Japan(6)) and incidence is increasing.(7) In 2002 approximately 600,000 people died of liver cancer including 13,000 in the United States, 57,000(5) in Europe and approximately 360,000 in China, Korea and Japan.(6) Currently, the 5-year survival rate for liver cancer patients in the United States is 11 percent.(8)

"The American Liver Foundation (ALF) is always pleased when new therapies prove effective for those affected by liver disease. Researchers worldwide, including those supported by ALF, have spent decades studying liver cancer," said James L. Boyer, M.D., chairman, board of directors, American Liver Foundation. "This new treatment provides a valuable option for liver cancer patients and will enable ALF to further promote the treatment of liver disease through our education and advocacy efforts."

The companies also announced that an innovative patient support program - Resources for Expert Assistance and Care Helpline (REACH(R)) - is available to answer questions about Nexavar treatment, reimbursement, and patient support. For more information, healthcare providers and patients may contact the REACH program at 1.866.NEXAVAR (1.866.639.2827).

Phase 3 Data Summary

The FDA approval was based on positive data from the international Phase 3 placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial which demonstrated that Nexavar improved overall survival by 44 percent in patients with HCC (HR=0.69; p=0.0006) versus placebo. In the study, median overall survival was 10.7 months in Nexavar-treated patients compared to 7.9 months in those taking placebo. No ind
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals,Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
2. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
5. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... LEIPZIG, Germany , Sept. 17, 2014 ... entered into an exclusive technology development partnership with ... agents to image CD4+ positive immune T cells. ... capability to precisely diagnose and determine therapeutic options ... The ability to image CD4+ T-cells will also ...
(Date:9/17/2014)... , Sept. 17, 2014   GS1 ... how to implement GS1 Standards to support the ... enhance patient safety and security in the pharmaceutical ... GS1 Standards to U.S. Pharmaceutical Supply Chain Business ... Act , was developed in collaboration with ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... announced that it has earned a $4 million ... AKAO ) associated with the initiation of a ... serious multi-drug resistant (MDR), gram-negative bacterial infections.  The ... study to evaluate the efficacy and safety of ...
Breaking Medicine Technology:ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
(Date:9/17/2014)... A ball gown is the most formal ... full-skirted gown reaching the floor, made of luxurious fabric, ... occasion gown manufacturer and retailer, has delightedly unveiled its ... gowns are offered at discounted rates. , Most versions ... gowns are typically worn with a stole (a formal ...
(Date:9/17/2014)... September 18, 2014 The National Resident ... Match , a comprehensive analysis of the relationship between ... preferred specialty. The new edition is based on ... specialty for U.S. allopathic medical school senior students and ... be able to provide this new edition of Charting ...
(Date:9/17/2014)... September 17, 2014 In its latest ... drug and alcohol treatment program that gets clients off ... foundation in recovery they can believe in, is exploring ... 20% of Americans who are afflicted with depression are ... Forever Recovery’s CEO Per Wickstrom . “Unfortunately, these ...
(Date:9/17/2014)... for the very healthy. Astronauts are selected for ... psychological standards to prepare them for any unknown ... average people can now fly for enjoyment. The ... about what medical conditions or diseases should be ... most medical conditions have never been studied for ...
(Date:9/17/2014)... latest blog post, Best Drug Rehabilitation , which offers ... a stay in rehab can make a big difference in ... member of the therapeutic care team that is making a ... and around the world: dogs. , “Studies show ... and stress levels in recovering addicts,” commented Best Drug Rehabilitation’s ...
Breaking Medicine News(10 mins):Health News:Fecbek.com: Ladies Can Be Elegant Enough to Draw Everyone’s Attention by Wearing Trendy Ball Gowns 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 2Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 3Health News:Space: The final frontier… open to the public 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2
... surgeon Alexander Vaccaro, M.D., timing of surgery is crucial in ... of great argument among the orthopaedic surgeons. ,Should ... to try to limit the damage to the spinal cord ... make a difference in how a patient ultimately fares, as ...
... disease, has been established by researchers from the Jean Mayer// ... , ,The study involved examination of apolipoprotein A5 ... a vital role in fat metabolism in the blood. A ... heart disease, which can be altered by consumption of high ...
... juices is not linked with preschoolers being overweight, ... in the October issue of Pediatrics, the// leading ... Pediatrics (AAP). This latest analysis of the largest ... Health and Nutritional Examination Survey 1999-2002) finds no ...
... Minister Ram Vilas Paswan promises a new policy for the ... subsidised treatment for// tuberculosis, AIDS and cancer. ,"By ... district headquarters that will offer free medication to the poor," ... will be stocked with the help of the drug manufacturers ...
... against flu, researchers at the University of Wisconsin-Madison have ... broad protection// against influenza viruses, including deadly avian influenza. ... (Oct. 4, 2006) in the Journal of Virology, describes ... molecule -- that effectively blocks the influenza virus from ...
... Lucknow: An Uttar Pradesh villager suffering from a serious ... floor of a premier hospital here//, apparently because he ... man jumped out of a window of the nephrology ... Medical Sciences, where he was being treated, hospital sources ...
Cached Medicine News:Health News:Study on Timing of Spinal Surgery 2Health News:Study on Timing of Spinal Surgery 3Health News:The interplay of genes, diet and heart disease 2Health News:The interplay of genes, diet and heart disease 3Health News:The interplay of genes, diet and heart disease 4Health News:Fruit Juice Intake Among Preschool Children Not Associated with Weight 2Health News:Free Medicines, Health Insurance for Poor Soon: Paswan 2Health News:New Drug Blocks Influenza, Including Bird Flu Virus 2Health News:New Drug Blocks Influenza, Including Bird Flu Virus 3
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
... Minifold I system consists of four basic components: ... and metal clamping plate (see diagram). The sample ... producing spots, dots, or slots (see below). All ... as an accessory plate in conjunction with a ...
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
... and Bio-Dot SF (slot format) microfiltration units ... or nucleic acid in solution onto nitrocellulose ... be accommodated by using interchangeable templates to ... slot format Bio-Dot SF apparatus. Each is ...
Medicine Products: